Workflow
SPG(600529)
icon
Search documents
山东药玻(600529) - 2014 Q4 - 年度财报
2015-04-21 16:00
Financial Performance - The company's operating revenue for 2014 was CNY 1,691,112,456.28, representing a year-on-year increase of 9.49% compared to CNY 1,544,544,952.06 in 2013[22] - The net profit attributable to shareholders of the listed company was CNY 124,702,667.08, a slight increase of 1.94% from CNY 122,333,707.19 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 126,377,897.68, which is a 5.89% increase from CNY 119,348,682.23 in 2013[22] - The total profit amounted to CNY 16,837,950, an increase of 2.45% compared to the previous year[29] - The company achieved operating revenue of CNY 1,691,112,456.28, representing a year-on-year increase of 9.49%[31] - Total revenue for the company reached ¥1,658,741,321.87, representing a year-over-year increase of 9.48%[41] - The gross profit margin decreased to 26.58%, down by 2.47 percentage points compared to the previous year[41] - The company reported a net profit margin improvement, with retained earnings increasing to ¥1,051,882,405.05 from ¥978,773,594.28, a rise of about 7.5%[122] - The company reported a total profit of ¥168,379,522.80, up from ¥164,357,231.83, representing a growth of 2.5%[130] Assets and Liabilities - The total assets at the end of 2014 amounted to CNY 2,818,180,079.30, reflecting a 4.14% increase from CNY 2,706,032,008.40 in 2013[22] - The net assets attributable to shareholders of the listed company were CNY 2,116,330,672.48, up 4.25% from CNY 2,029,982,702.03 in the previous year[22] - The debt-to-asset ratio improved to 24.57%, a decrease of 0.4 percentage points from the previous year[30] - Total current assets increased to ¥1,526,403,446.05 from ¥1,416,562,532.61, representing a growth of approximately 7.7%[120] - Total liabilities increased to ¥692,561,460.85 from ¥676,049,306.37, which is an increase of approximately 2.3%[122] - The total equity increased to ¥2,101,405,961.48 from ¥2,009,417,419.45, marking a growth of 4.6%[126] Cash Flow - The company’s cash flow from operating activities was CNY 266,634,293.79, a slight decrease of 0.73% compared to the previous year[38] - Cash flow from operating activities was ¥1,927,201,827.10, compared to ¥1,699,360,110.59 in the previous year, indicating a rise of 13.4%[135] - The net increase in cash and cash equivalents for the year was CNY 63,496,187.08, compared to CNY 49,105,510.53 in the previous year[140] - Total cash inflow from operating activities amounted to CNY 1,787,806,533.88, up from CNY 1,630,159,726.91, representing a growth of 9.7%[139] Dividends and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.50 per 10 shares, totaling CNY 38,607,016.65[2] - The cash dividend ratio for 2014 was 30.96%, with a total cash dividend amounting to 38,607,016.65 RMB[61] - The total number of shareholders at the end of the reporting period was 23,718, an increase from 21,589 five trading days prior[72] - The largest shareholder, Yiyuan County Public Asset Management Committee, holds 47,540,759 shares, representing 18.47% of total shares[74] Governance and Management - The company has maintained a stable management structure with no significant changes in the board composition during the reporting period[83] - The total remuneration for the board members and senior management during the reporting period amounted to 1,064,160 RMB (before tax)[83] - The company continues to focus on maintaining strong governance and oversight through its independent directors[83] - The independent directors did not raise any objections to the board's proposals during the reporting period[103] - The company has implemented a strict insider information management system to comply with regulatory requirements[98] Strategic Goals and Market Position - The company plans to achieve an annual revenue of 1.8 billion RMB in 2015, with a projected operating tax and additional fees of 1.62 billion RMB[57] - The company aims to maintain stable growth in export revenue, leveraging its brand advantages in markets such as the EU, Africa, Latin America, and Southeast Asia[55] - The company has set a long-term goal of building a "century-old pharmaceutical glass" brand, focusing on high-value, low-energy products for market expansion[56] - The company is committed to enhancing quality control to meet customer demands and strengthen its competitive position in the pharmaceutical packaging industry[55] Compliance and Reporting - The company’s financial statements comply with the requirements of the enterprise accounting standards, reflecting its financial position and operating results accurately[166] - The company has not faced any penalties or rectification measures from its board, supervisors, senior management, or major shareholders[68] - The company has not reported any significant changes in employee compensation standards or other regulations[69] - The company held its annual shareholders' meeting on May 17, 2014, where all proposed resolutions were approved, including the financial report for the year 2013[100] Research and Development - The company received 24 patent authorizations during the reporting period, including 2 invention patents, reinforcing its technological leadership[47] - The company focused on enhancing automation in production, which improved product competitiveness and reduced costs[29]
山东药玻(600529) - 2015 Q1 - 季度财报
2015-04-21 16:00
Financial Performance - Operating income rose by 6.63% to CNY 415,868,291.43 year-on-year[6] - Net profit attributable to shareholders increased by 8.09% to CNY 32,188,025.00 compared to the same period last year[6] - Basic earnings per share rose by 8.33% to CNY 0.13[6] - Total operating revenue for the current period reached ¥415,868,291.43, an increase of 6.9% compared to ¥390,024,307.40 in the previous period[23] - Net profit for the current period was ¥32,196,707.39, which is a 7.5% increase compared to ¥29,899,737.94 from the previous period[24] - Earnings per share (EPS) for the current period was ¥0.13, up from ¥0.12 in the previous period, indicating a growth of 8.3%[25] Cash Flow - Cash flow from operating activities surged by 60.52% to CNY 70,509,040.49 year-on-year[6] - Cash inflow from operating activities totaled ¥471,678,106.76, an increase from ¥421,634,471.19 in the previous period, marking a growth of 11.9%[30] - Operating cash flow net amount for Q1 2015 was CNY 66,678,040.75, an increase of 50.8% compared to CNY 44,220,744.62 in the previous period[35] - The total cash inflow from operating activities was CNY 437,788,114.26, up from CNY 390,908,750.07 in the previous period, reflecting an increase of 12.0%[35] - The cash flow from financing activities net amount was CNY 30,612,955.33, a recovery from a negative cash flow of -CNY 31,007,324.94 in the previous period[36] Assets and Liabilities - Total assets increased by 2.73% to CNY 2,895,220,083.86 compared to the end of the previous year[6] - Total liabilities amounted to CNY 738,075,110.57, up from CNY 692,561,460.85, indicating an increase of approximately 6.56%[18] - Current liabilities totaled CNY 738,075,110.57, reflecting an increase from CNY 692,561,460.85, which is a growth of about 6.56%[18] - The company's equity attributable to shareholders reached CNY 2,148,055,018.11, up from CNY 2,116,330,672.48, representing an increase of approximately 1.5%[18] - Current assets totaled CNY 1,603,632,685.83, an increase from CNY 1,526,403,446.05, reflecting a growth of about 5.06%[17] Expenses - Sales expenses increased by 30.18% due to higher product sales and increased freight and travel costs[12] - Management expenses increased by 39.55% primarily due to higher product quality management costs[12] - Total operating costs amounted to ¥373,300,540.65, up from ¥349,820,478.22, reflecting a growth of 6.7%[23] - Sales expenses increased to ¥40,851,492.89 from ¥31,381,634.99, reflecting a rise of 30.5%[24] - Management expenses rose to ¥30,874,311.73, compared to ¥22,124,442.12, indicating an increase of 39.5%[24] Investments - Cash outflow for investment activities totaled CNY 69,953,539.03, compared to CNY 30,186,347.83 in the previous period, representing a 131.7% increase[35] - The company reported a net cash flow from investment activities of -CNY 69,931,866.02, worsening from -CNY 30,186,347.83 in the previous period[35] Other Financial Metrics - The weighted average return on net assets increased by 0.06 percentage points to 1.52%[6] - Financial expenses decreased to ¥419,454.76 from ¥1,125,476.40, showing a reduction of 62.8%[24] - The company reported an increase in comprehensive income to ¥32,196,707.39 from ¥29,899,737.94, reflecting a growth of 7.5%[25]
山东药玻(600529) - 2014 Q3 - 季度财报
2014-10-27 16:00
2014 年第三季度报告 1 / 18 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司主要财务数据和股东变化 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 7 | 2014 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员应当保证季度报告内容的真实、准确、完 整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。 1.2 公司八名董事出席董事会审议季度报告,王兴军董事因公务出差未参加本次会议。 二、 公司主要财务数据和股东变化 2.1 主要财务数据 单位:元 币种:人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 2,844,153,564.93 | 2,705,463,004.13 | | 5.13 | | 归属于上市公司 | 2,088,651,637.29 | 2,029,982,702.03 | | 2.8 ...
山东药玻(600529) - 2014 Q2 - 季度财报
2014-07-21 16:00
Financial Performance - The company achieved operating revenue of 813,544,477.91 RMB, a year-on-year increase of 7.20% compared to 758,927,999.57 RMB in the same period last year[16]. - The net profit attributable to shareholders was 67,418,001.79 RMB, showing a slight increase of 0.20% from 67,280,743.45 RMB in the previous year[16]. - The basic earnings per share for the period was 0.2619 RMB, up 0.19% from 0.2614 RMB in the same period last year[16]. - The main business income for the period was 79,733,000 RMB, reflecting a year-on-year growth of 7.11% driven by increased sales of molded and brown bottle series products[17]. - The company reported a total operating revenue for the first half of 2014 of CNY 797,325,638.45, representing a year-on-year increase of 7.11%[22]. - The company reported a total operating cost of CNY 723,348,899.14, which is an increase of 7.4% from CNY 673,178,861.48 in the previous year[49]. - The company reported a net cash flow from operating activities of 100,986,732.22 RMB, a decrease of 8.16% compared to 109,961,830.10 RMB in the same period last year[16]. Assets and Liabilities - The total assets at the end of the reporting period were 2,772,394,872.00 RMB, an increase of 2.47% from 2,705,463,004.13 RMB at the end of the previous year[16]. - The company's current assets totaled CNY 1,510,089,746.53, up from CNY 1,424,464,099.28 at the start of the year, reflecting a growth of approximately 6.0%[39]. - Total liabilities amounted to CNY 715,933,933.73, compared to CNY 675,480,302.10 at the beginning of the year, marking an increase of approximately 6.0%[43]. - The company's equity attributable to shareholders reached CNY 2,056,460,938.17, up from CNY 2,029,982,702.03, reflecting a growth of about 1.3%[43]. - The total assets of Shandong Pharmaceutical Glass Co., Ltd. as of June 30, 2014, amounted to CNY 2,772,394,871.90, an increase from CNY 2,705,463,004.13 at the beginning of the year[39]. Cash Flow and Investments - The company reported a net cash flow from investing activities of -CNY 71,317,834.12, worsening from -CNY 39,900,533.11 year-on-year[56]. - Cash inflow from financing activities was CNY 75,000,000.00, down from CNY 85,000,000.00, indicating a decrease of 11.8%[56]. - The net cash flow from financing activities was -CNY 13,893,591.50, an improvement from -CNY 32,274,560.63 in the previous year[56]. - The company’s cash inflow from sales of goods and services reached CNY 878,211,000.78, slightly higher than CNY 868,415,107.56 from the previous year[53]. Shareholder Information - The total number of shareholders at the end of the reporting period was 25,447, with the largest shareholder holding 18.47% of the shares[32]. - The company declared a cash dividend of CNY 1.50 per share, totaling CNY 38,607,016.65, which was distributed on July 11, 2014[26]. - The total equity attributable to the parent company at the end of June 2014 was CNY 2,056,460,938.17, up from CNY 1,940,346,924.02 at the end of the previous year, representing an increase of approximately 6%[69]. Operational Challenges and Strategies - The company faced challenges including rising accounts receivable and increased labor costs, which impacted operational efficiency[18]. - The company plans to enhance its sales incentive policies and tighten accounts receivable management to improve cash flow efficiency[18]. - The company is actively responding to national environmental policies, which has led to increased production costs but aims to improve product quality through technological innovation[18]. Market and Product Information - The company primarily produces pharmaceutical packaging products, including molded bottles, ampoules, and aluminum-plastic cap plastic bottles[87]. - The company continues to focus on expanding its product lines and enhancing operational efficiency to drive future growth[200]. Compliance and Governance - The financial report for the first half of 2014 was approved by the board of directors on July 19, 2014[88]. - The company adheres to the accounting standards issued by the Ministry of Finance, ensuring the financial statements reflect its financial status accurately[90]. - The company has a commitment to transparency and compliance with relevant regulations in its financial reporting[90].
山东药玻(600529) - 2013 Q4 - 年度财报
2014-04-21 16:00
Financial Performance - The company's operating revenue for 2013 was CNY 1,544,544,952.06, representing a 5.21% increase compared to CNY 1,468,092,831.37 in 2012[24] - The net profit attributable to shareholders for 2013 was CNY 122,333,707.19, a 2.09% increase from CNY 119,828,142.41 in 2012[24] - The basic earnings per share for 2013 was CNY 0.48, up from CNY 0.47 in 2012, reflecting a 2.09% increase[22] - The net cash flow from operating activities for 2013 was CNY 268,597,934.04, a significant increase of 841.81% compared to CNY 28,519,302.50 in 2012[24] - The total assets at the end of 2013 were CNY 2,705,463,004.13, which is a 3.57% increase from CNY 2,612,144,674.05 at the end of 2012[24] - The net assets attributable to shareholders at the end of 2013 were CNY 2,029,982,702.03, a 4.62% increase from CNY 1,940,346,924.02 at the end of 2012[24] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.50 per 10 shares to all shareholders, based on a total share capital of 257,380,111 shares as of the end of 2013[7] - The company has a cash dividend policy in place, with a cash dividend of 122,333,707.19 yuan proposed for the year 2013, representing 31.56% of the net profit attributable to shareholders[48] - The total number of shares for Shandong Pharmaceutical Glass Co., Ltd. is 257,380,111, with 100% being tradable shares[55] - The largest shareholder, Yiyuan County Public Asset Management Committee, holds 18.47% of the shares, totaling 47,540,759 shares[58] - The total number of shareholders at the end of the reporting period was 27,852, compared to 27,393 five trading days before the report[58] Market and Sales Performance - International market sales accounted for approximately 30% of total sales, with a growth rate of 7.07%[30] - The sales volume of the molded bottle series was 886,466,000 units, generating revenue of CNY 69,199,890, a year-on-year increase of 4.76%[31] - The company plans to continue expanding its international market presence to offset domestic market slowdowns[30] Financial Ratios and Expenses - The weighted average return on equity for 2013 was 6.17%, slightly down from 6.33% in 2012[22] - The company reduced its debt-to-asset ratio to 24.97%, a decrease of 0.75 percentage points from the previous year[29] - The financial expenses increased by 74.82% to CNY 10,429,011.72, primarily due to increased exchange losses[35] Research and Development - The company has obtained 26 patent authorizations during the reporting period, including 4 invention patents, 16 utility model patents, and 6 design patents, reinforcing its technological leadership in the industry[40] - The company has a well-established R&D system, recognized as a provincial engineering technology research center, which supports product upgrades and quality improvements[40] Corporate Governance and Management - The company has no significant litigation or arbitration matters during the reporting period, indicating a stable operational environment[50] - The company has implemented a robust internal control system to ensure compliance with legal and regulatory requirements[80] - The total remuneration for the board members and senior management during the reporting period amounted to 1.943 million yuan before tax[65] - The company emphasizes respect for stakeholders' rights, including creditors, employees, suppliers, customers, and the community, to promote sustainable development[82] Employee Information - The number of employees in the parent company was 4,132, while the total number of employees across the company and its subsidiaries was 4,488[75] - The total number of employees with a bachelor's degree or above is 704, while 1,200 employees have a college diploma[75] Accounting and Financial Reporting - The financial statements are prepared based on the going concern principle and the accrual basis of accounting, using historical cost for measurement[146] - The company adheres to the accounting standards issued by the Ministry of Finance, ensuring that financial reports accurately reflect its financial position and operating results[147] - The company recognizes goodwill in cases where the initial investment cost exceeds the fair value of identifiable net assets acquired in a business combination[154] Asset Management - The company's total assets at the end of the year were CNY 1,940,346,924.02, indicating stability in its asset base[120] - The total owner's equity at the end of the period is CNY 2,029,982,702.03, an increase from CNY 1,849,746,623.21 in the previous year, representing an increase of approximately 9.5%[123]
山东药玻(600529) - 2014 Q1 - 季度财报
2014-04-21 16:00
Financial Performance - Operating revenue for the first quarter was CNY 390,024,307.40, representing a year-on-year growth of 9.19%[10] - Net profit attributable to shareholders decreased to CNY 29,899,737.94, down 4.91% from the same period last year[10] - Total operating revenue for the first quarter of 2014 was CNY 390,024,307.40, an increase of 9.2% compared to CNY 357,205,871.04 in the same period last year[26] - Total operating costs rose to CNY 349,820,478.22, up 10.6% from CNY 316,231,370.01 year-over-year[26] - Net profit for the first quarter was CNY 29,899,737.94, a decrease of 4.9% from CNY 31,443,301.37 in the previous year[26] - Basic and diluted earnings per share remained stable at CNY 0.12, unchanged from the same period last year[29] Cash Flow - Net cash flow from operating activities increased significantly by 64.14% to CNY 43,924,546.87 compared to the previous year[10] - Cash flow from operating activities generated a net inflow of CNY 43,924,546.87, significantly higher than CNY 26,760,705.46 in the previous year[33] - The net cash flow from operating activities increased to ¥44,220,744.62, compared to ¥23,012,991.61 in the previous period, representing an increase of approximately 92.1%[37] - Total cash inflow from operating activities was ¥390,908,750.07, up from ¥387,015,918.87, indicating a slight increase of about 0.75%[37] - Cash outflow from operating activities decreased to ¥346,688,005.45 from ¥364,002,927.26, a reduction of approximately 4.7%[37] - The ending cash and cash equivalents balance was ¥156,191,723.95, compared to ¥126,977,067.40 at the end of the previous period, reflecting an increase of approximately 23.0%[38] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,708,502,230.32, a slight increase of 0.11% compared to the end of the previous year[10] - Total assets increased to CNY 2,708,502,230.32 from CNY 2,705,463,004.13, reflecting a slight growth of 0.04%[20] - Current assets rose to CNY 1,439,004,969.52, up from CNY 1,424,464,099.28, indicating an increase of 1.03%[20] - Total liabilities decreased to CNY 650,122,430.15 from CNY 675,480,302.10, a reduction of 3.73%[21] - Current liabilities totaled CNY 650,122,430.15, down from CNY 675,480,302.10, showing a decrease of 3.73%[21] - Shareholders' equity increased to CNY 2,058,379,800.17 from CNY 2,029,982,702.03, reflecting a growth of 1.45%[21] - Undistributed profits rose to CNY 1,008,673,332.22 from CNY 978,773,594.28, an increase of 3.66%[21] - Non-current assets totaled CNY 1,269,497,260.80, down from CNY 1,280,998,904.85, indicating a decrease of 0.73%[20] Expenses - Financial expenses decreased by CNY 1,721,308.11, a reduction of 60.46% attributed to decreased exchange losses[16] - Sales expenses decreased slightly to CNY 31,381,634.99 from CNY 32,360,470.10 year-over-year[26] - Financial expenses decreased significantly to CNY 1,125,476.40 from CNY 2,846,784.51 in the previous year[26] - The company reported an increase in management expenses to CNY 22,124,442.12, up from CNY 20,365,627.23 year-over-year[26] - The company incurred an asset impairment loss of CNY 747,962.85, compared to a gain of CNY 256,058.48 in the previous year[26] - Tax payable increased by CNY 5,873,420.84, reflecting a significant rise of 283.55% due to increased tax obligations[16] Shareholder Information - The company's total number of shareholders reached 27,009 at the end of the reporting period[14]